The present invention relates to an aerosol spray device for administration of a substance, specifically a substance having a disagreeable taste, such as nicotine, to the oral cavity of a subject; to an actuator included in said spray device and to methods for delivering the substance.
Oral administration of a substance, such as a drug or medicament, is frequently used, such as in the form of aerosol sprays for inhalation for the treatment of asthma. Another area of oral administration of a substance, such as a drug or medicament, is the area of nicotine-replacement therapy to give up smoking. Several apparatuses for the administration of nicotine containing aerosols have been described, such as in U.S. Pat. No. 5,810,018, U.S. Pat. No. 4,593,572 and U.S. Pat. No. 4,945,929.
One problem experienced with such medicaments being inhaled or administered locally in the oral cavity is the effects of substances having a disagreeable taste being distributed to the oral cavity of an individual. This is a problem in general with irritating and bad tasting drug substances and specifically a problem with nicotine. Such substances are influencing the taste and irritation sensory sites in the mouth and can cause problems when administered locally in the oral cavity to be absorbed through the oral mucosa. This is a particular problem when the drug is deposited on the back of the tongue where there is a high density of taste buds and in the upper throat where reflexes for nausea can be triggered.
When using traditional equipment for oral administration of an aerosol spray, a large part of the administered dose will end up in the whole oral cavity, the pharynx and/or the bronchial tree of the respiratory tract depending on the droplet size. Medicaments associated with inhalation, such as asthma drugs, are preferentially applied locally in the respiratory tract and lungs for a rapid and efficient effect. Still, not all orally sprayed medicaments are to be delivered to the respiratory tract and lungs, but are given locally in the oral cavity for uptake through the oral mucous membrane.
One such medicament is nicotine. Nicotine is an organic compound that is the principal alkaloid of tobacco. Nicotine is the chief addictive ingredient in the tobacco used in cigarettes, cigars, snuff and the like. Nicotine is also an addictive drug, though, and smokers characteristically display a strong tendency to relapse after having successfully stopped smoking for a time. Nicotine is the worlds second most used drug, after caffeine from coffee and tea.
The main problem with tobacco smoking is its enormous implications on health. Today it is estimated that smoking related diseases cause some 3-4 million deaths per year. This grim consequence of tobacco smoking has urged many medical associations and health authorities to take very strong actions against the use of tobacco.
Tobacco smoking can result in a dependence disorder. The WHO has in its International Classification of Disorders a diagnosis called Tobacco Dependence. Others like the American Psychiatric Association call the addiction Nicotine Dependence. Even though tobacco smoking is decreasing in many developed countries today it is hard to see how the societies could get rid of the worlds second most used drug.
Nicotine containing medications are currently the dominating treatments for tobacco dependence. There is also evidence of broader use of these medications like for smoking reduction and long term maintenance/substitution.
When smoking a cigarette, nicotine is quickly absorbed into the smoker's blood and reaches the brain within eight seconds after inhalation. The poisonous, toxic, carcinogenic, and addictive nature of smoking has provided efforts for methods, compositions and devices, which help in breaking the habit of smoking cigarettes.
For those who are unable to give up smoking there are several ways and forms of nicotine replacement products available on the market; such as nicotine gum. Several methods and means have been described for diminishing the desire of a subject to use tobacco, which comprises the step of administering to the subject nicotine or a derivative thereof as described in e.g. U.S. Pat. No. 5,939,100, U.S. Pat. No. 4,967,773, U.S. Pat. No. 865,026, U.S. Pat. No. 940,521. Aerosol compositions are described in GB 1 528 391, GB 2 030 862, U.S. Pat. No. 5,810,018, EP 0 557 129 and U.S. Pat. No. 4,593,572 and are adapted to be sprayed into the mouth of the user. Also, inhaling devices resembling a cigarette are known for ingestion of nicotine vapours orally as suggested in U.S. Pat. No. 5,167,242. Finally, ways of administrating nicotine is by way of delivering directly into the nasal cavity is known from U.S. Pat. No. 4,579,858, DE 32 41 437 and WO/93 127 64. Said means and methods address the problems associated with addiction to nicotine.
However, as stated above, a major drawback with the presently available nicotine containing aerosol spray devices is the fact that they deliver a large part of the dose in the back of the mouth cavity. This generally results in an experience of a bad and disagreeable taste, nausea and other irritations.
Several proposals have been provided for solving said problem of bad and disagreeable taste. Flavourants, such as tobacco flavouring, menthol or methyl salicylate, for example, may be added to impregnate such nicotine taste to produce an oral nicotine spray with a pharmacologically acceptable flavour. U.S. Pat. No. 4,967,773 describes the addition of liquorice, cocoa, aniseed and peppermint to a nicotine lozenge to avoid the bad taste of nicotine.
Still, none of the above mentioned means and methods addresses the problems associated with the bad taste of nicotine in any other way but addition of different flavouring agents.
Even though flavouring to conceal the bad taste of a medicament may partly circumvent the problem of bad tasting drugs it includes the further step in the production of the medicament of adding the desired flavouring agent. Moreover, addition of a flavourant may not conceal the taste or the irritating effect very well or long enough.
WO 95/20 411 describes a method of converting a medicament to a form usable for administration of the medicament to the airways or respiratory tracts of mammals. This is to bring the medicament to the location where it will do most good on people suffering from respiratory problems, such as asthma.
WO 99/6550 describes an inhalation device for providing pulmonary medicament for inhalation where the inhalation device includes a vortex generator. The vortex created through this vortex generator gives the smoker a feeling of “mouthfulness” close to what is experienced when smoking a cigarette.
GB 2 308 992 A describes a nebulizer for administering an aerosol to the lungs of patients requiring respiratory therapy, by producing a large number of small droplets and fewer large droplets in the aerosol produced by the nebulizer.
All said devices for oral administration describe means and methods for specific local delivery into the respiratory tracts, where the aim is to avoid as much as possible of the aerosol to deposit in the oral cavity.
Thus, there is a need for a delivery system, which solves the above mentioned problems associated with oral administration of substances, such as drugs and medicaments, having a bad, irritating or otherwise disagreeable taste and at the same time achieve an efficient medication, i.e. an efficient blood concentration of the substance.
The main object of the present invention is to provide means and methods for overcoming the disadvantages and solving the problems associated with the foregoing known devices for oral delivery of a substance having a bad or disagreeable taste and/or being a source of irritation.
A further object of the present invention is to provide means and methods for overcoming the above disadvantages and solving the above problems while at the same time achieving an efficient absorption of the substance.
Further objects of the invention will appear from the following description and the appending claims.
To fulfil these objects the present invention relates to an aerosol spray device for administering a substance to the oral cavity of a subject, said aerosol spray device comprising an actuator having an actuator head with a defined axis and at least one orifice the actuator head being constructed to dispense the aerosol spray containing the substance in the front of the oral cavity of the subject.
The invention also relates to an actuator being adapted to be used in such an aerosol spray device.
Furthermore, the invention refers to a method for oral administration of a substance to a subject, comprising delivering an aerosol spray containing the substance to the front of the oral cavity of the subject.
In one embodiment the invention refers to a method of assisting in the reduction of the desire of a subject to use nicotine or nicotine containing compositions, comprising delivering a nicotine containing aerosol spray to the front of the oral cavity of the subject.
By means of the means and methods provided by the present invention a bad and disagreeable taste of a drug may be reduced or substantially avoided resulting in better compliance, less irritation and other untoward effects, which in turn means more efficient therapy.
We have surprisingly found that by administering the above type of substance in the front of the oral cavity, such as below the tongue or between the lips and the teeth the experience of bad and disagreeable taste and irritation may be largely reduced or substantially eliminated at the same time as the effect of the substance is substantially maintained.
The term “aerosol spray device” is intended to mean a device for atomisation, dispersion and mixing of a fluid or powdery substance for the production of an aerosol.
The term “actuator” is intended to mean a means for delivering and controlling a spray or fine mist. The actuator comprises, for this purpose, an actuator head having an orifice for generation of a desired spray or spray pattern.
The term “administration to the oral cavity” is intended to mean delivering to and absorption in the oral cavity of a subject.
The term “disagreeable taste” is intended to mean any taste, which in general is regarded as bad, nasty, or gives negative associations, such as nausea and indigestion, or is a source of irritation to the recipient.
The term “irritation” is intended to mean irritating effects such as burning, acrid or stinging effects or the like.
The Aerosol Spray Device
In order to avoid a bad or disagreeable taste and irritation from a medicine substance, such as nicotine, we have found that the spray from a spray actuator has to be delivered to the front of the oral cavity of the subject receiving the substance. This is accomplished by means of a spray device according to the invention as described below in conjunction with the drawings. The spray or spray pattern delivered deposits the sprayed liquid in the front of the oral cavity either in front of the mandibular front teeth between the lips and the teeth, just behind the teeth or under the tongue, which thereby minimises bad taste and irritation. The actuator could be constructed according to, but not limited to the appended drawings.
With reference to
In
The spray devices shown in
In
The spray device according to
In
The spray device according to
The actuator according to the invention may be constructed in many different ways.
The spray actuator according to the invention comprises an actuator head having a defined axis and being provided with an orifice, where said orifice generates a spray or spray pattern directed in an angle of substantially 90±35 degrees from the actuator head axis.
The actuator may have different lengths and directions in relation to the spray bottle. The actuator head may be constructed into different forms, such as into the form of a divers mouthpiece or being provided with a flange in front of the actuator head with the aim of creating a distance between the lips and the teeth, thereby facilitate the delivering of the spray. The actuator head may also be constructed in an arched or curved form to follow the teeth and the orifices may then be distributed along part of or the whole arched or curved form.
The orifices may be of different size and shape, which will effect the spray pattern dispensed from the orifices. The actuator head may include one or more orifices. Preferable it includes many orifices, evenly distributed around the circumference of the actuator head. The sizes and the shape of holes may vary and is defined according to what is appropriate for the administration in question.
In one embodiment the actuator have a direction perpendicular to the axis of the spray bottle, as shown in the appended drawings, and the spray is directed in an angle of substantially 90 degrees to the axis a-a of the actuator head. Another embodiment may be an embodiment, where the actuator is directed along the axis of the spray bottle and the actuator head is directed substantially perpendicular to the actuator and axis of the spray bottle.
The spray bottle may be any known type, such as a pump spray or any other means for providing a spray. The spray may be provided by means of a pressurised gas.
The actuator may be made of any suitable material, such as a plastic material, or any other material well known within the art to be suitable for this type of device.
Mode of Administration
To obtain a local administration of the substance to the front of the oral cavity of a subject, the spray pattern delivering the substance is preferably directed in about 90±35 degrees to the actuator to minimize and/or exclude deposition of the substance in the back of the mouth. This will in turn reduce or substantially avoid the bad and unpleasant taste and irritating effect of a substance. A correct positioning of the device according to the invention, such as a as shown in the appended drawing, will give an administration in front of the oral cavity of a subject. Specifically the aerosol spray is administered to the front of the mandibular front teeth, i.e. in front of the teeth between the lips and the teeth, just behind the teeth or under the tongue.
Thus, in one embodiment the spray pattern delivering the substance is directed at an angle between about 55 and 125 degrees to the axis a-a of the end of the actuator nearest to the mouth.
In a further embodiment the spray pattern delivering the substance is directed at an angle between about 90 and about 125 degrees to the axis a-a of the end of the actuator nearest to the mouth; i.e. the spray is delivered upwards and obliquely backwards.
In a still further embodiment the spray pattern delivering the substance is directed at an angle of about 90 degrees to the axis a-a of the actuator; i.e. the spray is delivered substantially neither backwards nor forwards.
The examples below show that administration of an aerosol nicotine spray to the front of the oral cavity by means of an aerosol spray device adapted for such an administration reduces or substantially avoids the bad and unpleasant taste and irritating effect of a substance, while simultaneously giving substantially the same absorption and thereby effect of said substance.
Substances to be Administered
Suitable substances for distribution with the actuator according to the invention are any drug or medicament suitable for oral administration giving a bad and unpleasant taste and/or irritating effect. Examples of such substances are alkaloids, such as nicotine, nicotine salts and esters, other nicotine derivatives, lobeline, lobeline salts and esters, other lobeline derivatives; meclozine diphenhydralamine and promethazin.
Nicotine is a good example of an irritating substance with a less pleasant taste. Administering such substances via a mouth spray, vapour or aerosol is problematic. When ingested in larger doses, nicotine is a highly toxic poison that causes vomiting and nausea, headaches, stomach pains, and, in severe cases, convulsions, paralysis, and death. Even ingested in minor doses, nicotine is still an irritating, strong and bad tasting compound causing e.g. irritation in the oral cavity and respiratory tracts. In order to reduce or avoid such irritation the substance in e.g. a spray should be administered to the frontal part of the mouth. The more frontal the less irritation and bad taste.
When administering nicotine it may be in the form of the free base.
The active substance, such as nicotine or any of the substances mentioned below, may be administered together with any suitable additive known within the art, such as flavourings, preservatives and alcohol.
Administration Methods
The invention refers to a method for oral administration of a substance to a subject, comprising delivering an aerosol spray containing the substance to the front of the oral cavity of the subject.
The substance may be any substance as described under Substances to be administered above.
In one embodiment the invention refers to a method for oral administration of nicotine to a subject, comprising delivering an aerosol spray containing nicotine to the front of the oral cavity of the subject.
In a further embodiment the invention refers to a method of assisting in the reduction of the desire of a subject to use nicotine or nicotine containing compositions, comprising delivering a nicotine containing aerosol spray to the front of the oral cavity of the subject.
The nicotine containing aerosol spray may be administered to the front of the mandibular front teeth, i.e. in front of the teeth between the lips and the teeth, to the area just behind the teeth or under the tongue. The doses of nicotine to be administered are well known within the art. Typical examples are 0.5-6 mg doses of nicotine, specifically 2-4 mg doses of nicotine.
The use of nicotine or a nicotine containing composition may be the use of cigarettes, cigars, snuff, chewing tobacco and the like.
The effect of administering 2 mg of nicotine at different sites in the mouth was studied in a study involving eight volunteer smokers. Each of 1A, 1B and 1C include all eight smokers. There was a three hours interval between the three administration conditions. The nicotine was administered in the form of a spray including in volume %:
In 1A and 1B the nicotine was administered to the following sites: 1A. in front of the mandibular front teeth, 1B below the tongue. In 1C, the control group, the nicotine spray was administered in the ordinary way according to general instructions given for nicotine sprays aiming at the sides of the mouth. The degree of irritation and unpleasant taste, respectively was rated at 5 min after application using a VAS (visual analogue scale, 100 mm; 0 mm means no irritation or unpleasant taste and 100 mm means maximal irritation and unpleasant taste, respectively). Blood tests were carried out immediately before and 15 minutes after the administration of the nicotine dose and the nicotine plasma levels were determined as the Δ plasma nicotine value.
The device used was a standard Nussbaum & Guhl pump.
Results:
As to the degree of irritation 1C was significantly higher than both 1A and 1B (p<0.01, two tailed test). As to the degree of unpleasant taste 1C was significantly higher than 1A (p<0.01, two tailed test) and 1C was also higher than 1B (p<0.05, two tailed test).
Example 1 shows that an administration of a nicotine spray in the front of the oral cavity gives less irritation and unpleasant taste compared to ordinary administration in the whole oral cavity. The absorption of nicotine, i.e. the effect of the nicotine is however not reduced.
A second experiment was performed using ten volunteer smokers. Each of 2A, 2B and 2C included all ten smokers. As in example 1 there was a three hours interval between the administration conditions. In 2A a 2 mg nicotine mouth spray using a standard Nussbaum & Guhl pump was used and the dose was administered in the same ordinary way according to general instructions given for nicotine sprays as in 1C above. In 2B 2 mg and in 2C 4 mg of nicotine was given by means of the device shown in
Said nicotine spray had the same composition as the spray in example 1 and irritation, unpleasant taste as well as Δ plasma nicotine were rated and measured in the same way as in example 1.
Results:
As to the degree of both irritation and unpleasant taste 2A was significantly higher than 2B (p<0.01, two tailed test) and the values of 2C was also significantly higher than 2B (p<0.01, two tailed test).
When comparing 2A and 2B this example 2 also shows that administration of the nicotine to the front of the oral cavity (2B), here the front of the mandibular front teeth, gives much less irritation and unpleasant taste compared to ordinary administration in the whole oral cavity (2A), still having substantially the same effect. 2C shows that a dose of 4 mg (double dose) administered in the front of the mandibular front teeth does not give more irritation and unpleasant taste than half the dose (2 mg) administered in the ordinary way into the whole oral cavity.
The experiment described in Example 2 was repeated using ten volunteer smokers. In 3A a 2 mg nicotine mouth spray using a standard Nussbaum & Guhl pump was used and in 3B 2 mg and 3C 4 mg of nicotine was given by means of the aerosol spray device shown in
Results:
As to the degree of both irritation and unpleasant taste 3A was significantly higher than 3B (p<0.01, two tailed test) and the values of 3C was also significantly higher than 3B (p<0.01, two tailed test).
Example 3 shows that administration of the nicotine spray by means of a device, such as a device according to the invention, adapted for administration of the spray into the very front of the oral cavity reduces both irritation and unpleasant taste, but not the absorption of nicotine.
Number | Date | Country | Kind |
---|---|---|---|
0102276 | Jun 2001 | SE | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/SE02/01231 | 6/24/2002 | WO | 00 | 12/23/2003 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO03/000324 | 1/3/2003 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
865026 | Ellis | Sep 1907 | A |
940521 | Endicott | Nov 1909 | A |
2933259 | Raskin | Apr 1960 | A |
3069314 | Jenkins | Dec 1962 | A |
3314578 | La Mura | Apr 1967 | A |
3767125 | Gehres et al. | Oct 1973 | A |
3777029 | Magid | Dec 1973 | A |
3877468 | Lichtneckert et al. | Apr 1975 | A |
4317837 | Kehoe et al. | Mar 1982 | A |
4579858 | Ferno | Apr 1986 | A |
4593572 | Linley, Jr. | Jun 1986 | A |
4655231 | Ray et al. | Apr 1987 | A |
4674491 | Brugger et al. | Jun 1987 | A |
4696315 | Summers | Sep 1987 | A |
4817640 | Summers | Apr 1989 | A |
4835162 | Abood | May 1989 | A |
4885173 | Stanley et al. | Dec 1989 | A |
4907605 | Ray et al. | Mar 1990 | A |
4920989 | Rose et al. | May 1990 | A |
4945929 | Egilmex | Aug 1990 | A |
4967733 | Rousseau | Nov 1990 | A |
4971079 | Talapin et al. | Nov 1990 | A |
5069904 | Masterson et al. | Dec 1991 | A |
5077104 | Hunt et al. | Dec 1991 | A |
5135753 | Baker et al. | Aug 1992 | A |
5167242 | Turner | Dec 1992 | A |
5268209 | Hunt et al. | Dec 1993 | A |
5284163 | Knudsen et al. | Feb 1994 | A |
5318523 | Lu | Jun 1994 | A |
5488962 | Perfetti et al. | Feb 1996 | A |
5501858 | Fuisz | Mar 1996 | A |
5507278 | Karell | Apr 1996 | A |
5525351 | Dam et al. | Jun 1996 | A |
5543424 | Carlsson et al. | Aug 1996 | A |
5549906 | Santus et al. | Aug 1996 | A |
5573774 | Keenan | Nov 1996 | A |
5643905 | Moormann et al. | Jul 1997 | A |
5654003 | Fuisz et al. | Aug 1997 | A |
5656255 | Jones et al. | Aug 1997 | A |
5692493 | Weinstein et al. | Dec 1997 | A |
5721257 | Baker et al. | Feb 1998 | A |
5733574 | Dam et al. | Mar 1998 | A |
5810018 | Monte | Sep 1998 | A |
5834011 | Rose et al. | Nov 1998 | A |
5939100 | Albrechtsen et al. | Aug 1999 | A |
5955098 | Dugger, III | Sep 1999 | A |
6024097 | Von Wielligh et al. | Feb 2000 | A |
6102036 | Slutsky et al. | Aug 2000 | A |
6110495 | Dam et al. | Aug 2000 | A |
6129936 | Gustafsson et al. | Oct 2000 | A |
6174496 | Stein | Jan 2001 | B1 |
6223744 | Garon | May 2001 | B1 |
6264981 | Zhang et al. | Jul 2001 | B1 |
6280761 | Santus et al. | Aug 2001 | B1 |
6344222 | Cherukuri et al. | Feb 2002 | B1 |
6358527 | Gilis et al. | Mar 2002 | B1 |
6841557 | Anderson et al. | Jan 2005 | B2 |
6845777 | Pera | Jan 2005 | B2 |
6849624 | Ballard et al. | Feb 2005 | B2 |
6855820 | Broom et al. | Feb 2005 | B2 |
6858624 | Hagen et al. | Feb 2005 | B2 |
6861434 | Stack | Mar 2005 | B2 |
6893654 | Pinney et al. | May 2005 | B2 |
6932971 | Bachmann et al. | Aug 2005 | B2 |
6958143 | Choi et al. | Oct 2005 | B2 |
6958323 | Olivera et al. | Oct 2005 | B2 |
6960574 | Prokai | Nov 2005 | B2 |
6982089 | Tobinick | Jan 2006 | B2 |
20010029959 | Burgard et al. | Oct 2001 | A1 |
20020009523 | Gustaesson | Jan 2002 | A1 |
20020010198 | Jerussi et al. | Jan 2002 | A1 |
20020015687 | Bellamy et al. | Feb 2002 | A1 |
20030077297 | Chen et al. | Apr 2003 | A1 |
20030082109 | Gorenstein | May 2003 | A1 |
20030124191 | Besse et al. | Jul 2003 | A1 |
20030180360 | Am Ende et al. | Sep 2003 | A1 |
20030224048 | Walling | Dec 2003 | A1 |
20040013752 | Wolfson | Jan 2004 | A1 |
20050009813 | Moormann et al. | Jan 2005 | A1 |
20050009882 | Farr | Jan 2005 | A1 |
20050013856 | Trivedi et al. | Jan 2005 | A1 |
20050020641 | Sellers et al. | Jan 2005 | A1 |
20050042173 | Besse et al. | Feb 2005 | A1 |
20050058609 | Nazeri | Mar 2005 | A1 |
20050089524 | Sanderson et al. | Apr 2005 | A1 |
20050100513 | Watkins et al. | May 2005 | A1 |
20050107397 | Galambos et al. | May 2005 | A1 |
20050118272 | Besse et al. | Jun 2005 | A1 |
20050123502 | Chan et al. | Jun 2005 | A1 |
20050136047 | Ennifar et al. | Jun 2005 | A1 |
20050182063 | Yohannes | Aug 2005 | A1 |
20050197343 | Gmeiner et al. | Sep 2005 | A1 |
20050222270 | Olney et al. | Oct 2005 | A1 |
20050227998 | Voelker | Oct 2005 | A1 |
20050261289 | Flohr et al. | Nov 2005 | A1 |
20050277626 | Dinan et al. | Dec 2005 | A1 |
20050282823 | Breining et al. | Dec 2005 | A1 |
20060057207 | Ziegler et al. | Mar 2006 | A1 |
20060058328 | Bhatti et al. | Mar 2006 | A1 |
20060062835 | Weil | Mar 2006 | A1 |
20060084656 | Ziegler et al. | Apr 2006 | A1 |
20060252773 | Ceci | Nov 2006 | A1 |
20060276551 | Shytle et al. | Dec 2006 | A1 |
Number | Date | Country |
---|---|---|
1089834 | Jul 1994 | CN |
1511550 | Jul 2004 | CN |
1557177 | Dec 2004 | CN |
2313996 | Oct 1974 | DE |
2526702 | Dec 1976 | DE |
3241437 | May 1984 | DE |
4301782 | Aug 1994 | DE |
19639343 | Apr 1998 | DE |
29800300 | Apr 1998 | DE |
19943491 | Mar 2001 | DE |
205133 | Dec 1986 | EP |
215682 | Mar 1987 | EP |
B0324794 | Jul 1989 | EP |
377520 | Jul 1990 | EP |
472428 | Feb 1992 | EP |
485421 | May 1992 | EP |
500658 | Sep 1992 | EP |
506774 | Oct 1992 | EP |
506860 | Oct 1992 | EP |
0557129 | Aug 1993 | EP |
570327 | Nov 1993 | EP |
0619729 | Oct 1994 | EP |
680326 | Nov 1995 | EP |
0745380 | Dec 1996 | EP |
0839544 | May 1998 | EP |
850182 | Jul 1998 | EP |
0904055 | Mar 1999 | EP |
0916339 | May 1999 | EP |
1023069 | Aug 2000 | EP |
1069900 | Jan 2001 | EP |
1136487 | Sep 2001 | EP |
1267849 | Jan 2003 | EP |
1272218 | Jan 2003 | EP |
1448196 | Aug 2004 | EP |
1 409 049 | Dec 2004 | EP |
1509227 | Mar 2005 | EP |
1534254 | Jun 2005 | EP |
1539149 | Jun 2005 | EP |
1539764 | Jun 2005 | EP |
1539765 | Jun 2005 | EP |
1551393 | Jul 2005 | EP |
1589952 | Nov 2005 | EP |
1624845 | Feb 2006 | EP |
1624895 | Feb 2006 | EP |
1634498 | Mar 2006 | EP |
1737431 | Jan 2007 | EP |
2147652 | Mar 1973 | FR |
2467604 | Apr 1981 | FR |
2608156 | Jun 1988 | FR |
2688400 | Sep 1993 | FR |
2698268 | May 1994 | FR |
2788982 | Aug 2000 | FR |
2792200 | Oct 2000 | FR |
1528391 | Oct 1978 | GB |
2030862 | Apr 1980 | GB |
2125699 | Mar 1984 | GB |
2255892 | Nov 1992 | GB |
2289204 | Nov 1995 | GB |
2308992 | Jul 1997 | GB |
2393392 | Mar 2004 | GB |
52114010 | Sep 1977 | JP |
62228022 | Oct 1987 | JP |
1243945 | Sep 1989 | JP |
2072118 | Mar 1990 | JP |
2005082587 | Mar 2005 | JP |
2005103113 | Apr 2005 | JP |
2005320342 | Nov 2005 | JP |
2001078976 | Aug 2001 | KP |
2029474 | Feb 1995 | RU |
1232260 | May 1986 | SU |
1268141 | Nov 1986 | SU |
WO-8302892 | Sep 1983 | WO |
WO-9101132 | Feb 1991 | WO |
WO-9101656 | Feb 1991 | WO |
WO-9104757 | Apr 1991 | WO |
WO-9106288 | May 1991 | WO |
WO-9109599 | Jul 1991 | WO |
WO-9109731 | Jul 1991 | WO |
WO 9312764 | Jul 1993 | WO |
WO-9416708 | Aug 1994 | WO |
WO-9503050 | Feb 1995 | WO |
WO 9520411 | Aug 1995 | WO |
WO-9702273 | Jan 1997 | WO |
WO-9710162 | Mar 1997 | WO |
WO-9742941 | Nov 1997 | WO |
WO-9915171 | Apr 1999 | WO |
WO 9965550 | Dec 1999 | WO |
WO-0019977 | Apr 2000 | WO |
WO-0038686 | Jul 2000 | WO |
WO-0044559 | Aug 2000 | WO |
WO-0045795 | Aug 2000 | WO |
WO-0056281 | Sep 2000 | WO |
WO-0119401 | Mar 2001 | WO |
WO-0130288 | May 2001 | WO |
WO-0137814 | May 2001 | WO |
WO-02076229 | Oct 2002 | WO |
WO-02102357 | Dec 2002 | WO |
WO-03013719 | Feb 2003 | WO |
WO-03045437 | Jun 2003 | WO |
WO-03053175 | Jul 2003 | WO |
WO-03055486 | Jul 2003 | WO |
WO-03077846 | Sep 2003 | WO |
WO-2004002446 | Jan 2004 | WO |
WO-2004004478 | Jan 2004 | WO |
WO-2004004479 | Jan 2004 | WO |
WO-2004004480 | Jan 2004 | WO |
WO-03061399 | Mar 2004 | WO |
WO-2004032644 | Apr 2004 | WO |
WO-2004056219 | Jul 2004 | WO |
WO-2004056363 | Jul 2004 | WO |
WO-2004064811 | Aug 2004 | WO |
WO-2004068964 | Aug 2004 | WO |
WO-2004068965 | Aug 2004 | WO |
WO-2004103372 | Dec 2004 | WO |
WO-2005007655 | Jan 2005 | WO |
WO-2005018348 | Mar 2005 | WO |
WO-2005023227 | Mar 2005 | WO |
WO-2005023781 | Mar 2005 | WO |
WO-2005028484 | Mar 2005 | WO |
WO-2005034968 | Apr 2005 | WO |
WO-2005040338 | May 2005 | WO |
WO-2005053691 | Jun 2005 | WO |
WO-2005066126 | Jul 2005 | WO |
WO-2006000232 | Jan 2006 | WO |
WO-2006008040 | Jan 2006 | WO |
WO-2006008041 | Jan 2006 | WO |
WO-2006028344 | Mar 2006 | WO |
WO-2006029349 | Mar 2006 | WO |
WO-2006037418 | Apr 2006 | WO |
WO-2006041769 | Apr 2006 | WO |
WO-2005084126 | Nov 2006 | WO |
WO-2006115202 | Nov 2006 | WO |
WO-2006119884 | Nov 2006 | WO |
WO-2006138682 | Dec 2006 | WO |
WO-2007006117 | Jan 2007 | WO |
Number | Date | Country | |
---|---|---|---|
20040159326 A1 | Aug 2004 | US |